 BENSALEM, Pa.--BUSINESS WIRE--- OMER CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Omeros Corporation Omeros or the Company NASDAQ: OMER investors concerning the Companys possible violations of federal securities laws. On October 1, 2021, Omeros announced that the U.S. Food and Drug Administration FDA had identified deficiencies with the Companys Biologics License Application for its drug candidate narsoplimab in the treatment of hematopoietic stem cell transpl 